On October 12, 2022, the State Administration of market supervision and Administration (the State Standardization Administration Committee) issued the Chinese national standard Announcement No. 13 of 2022, and the national standard: gb/t 41812-2022 general rules for performance testing of automatic pipetting workstations, which was drafted by Chengdu Shilian Health Biotechnology Co., Ltd., was published.
Gb/t 41812-2022 general rules for performance testing of automatic pipetting workstation was declared on January 9, 2020 and approved on April 8, 2020. It was jointly drafted by China Academy of testing technology, General Biology (Anhui) Co., Ltd., Chengdu Shilian Health Biotechnology Co., Ltd., Perkin Elmer enterprise management (Shanghai) Co., Ltd., West China Hospital of Sichuan University, and Shenzhen Huada Intelligent Manufacturing Technology Co., Ltd.
This standard specifies the general requirements, general principles and performance indicators of the performance test of the automatic pipetting workstation, and describes the performance test method and result calculation of the automatic pipetting workstation. This standard is applicable to the performance test of automatic pipetting workstation. The performance test of automatic nucleic acid extractor can refer to this standard. This standard unifies the performance indicators and detection methods of the automatic pipetting workstation, and solves the problem that the performance indicators of the workstation cannot be accurately measured and compared with each other. The issuance and implementation of this standard is conducive to standardizing the performance requirements of automatic pipetting workstation, maintaining the market order of automatic pipetting workstation, and laying a good foundation for the healthy development of automatic liquid processing industry. At the same time, it also promotes the development of automatic liquid treatment technology and domestic equipment in China.
Chengdu Shilian Health Biotechnology Co., Ltd., registered in August, 2018, was approved by the Chengdu high tech Zone government, Chengdu West China Cell Therapy Research Institute Co., Ltd. (West China Hospital), Sichuan West China maternal and Child Health Technology Co., Ltd. (West China Second Hospital), Sichuan West China oral health technology Co., Ltd. (West China oral hospital), and the national "973" The team of Professor tianweidong, the chief scientist of the key R & D program, was jointly invested and established to build a world-class and high standard research, development and transformation application platform of cell technology and cell drugs in Chengdu Frontier Medical Center. Phase I has completed the construction of a 3500 square meter platform, including a national cell information resource database (cell storage for tens of millions of people), a regional cell preparation center (adult stem cell, iPS cell and immune cell preparation) in six independent cell production workshops that meet the highest international standards, and a cell quality detection and inspection center that meets third-party services, forming a quality system traceable from the whole cycle of cell preparation, detection and storage. On the basis of existing resources and platforms, we will build a high-tech biotechnology enterprise featuring precision medicine and precision health, integrating cell technology research and development, achievement transformation, technical services and personnel training. Sichuan Cell Bank Co., Ltd. and Sichuan Tianfu cell quality detection and Evaluation Center Co., Ltd. have been established.
